Login to Your Account

Financings Roundup

Trius' TR-701 Antibiotic Heading Into Phase II with $30M Series B

By Jennifer Boggs

Monday, March 24, 2008
Antibacterial drug company Trius Therapeutics Inc. brought in $30 million in its second venture round to advance into Phase II and Phase III studies with lead program, TR-701, an oxazolidinone antibiotic that has indicated promising results from an ongoing Phase I study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription